References
- BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
- SewrightKAClarksonPMThompsonPDStatin myopathy: incidence, risk factors, and pathophysiologyCurr Atheroscler Rep2007938939618001622
- BaysHStatin safety: an overview and assessment of the data-2005Am J Cardiol200617;978A6C26C
- CanestaroWJAustinMAThummelKEGenetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic reviewGenet Med2014161181081924810685
- CarrDFO’MearaHJorgensenALSLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research DatalinkClin Pharmacol Ther201394669570123942138
- VooraDShahSHSpasojevicIThe SLCO1B1*5 genetic variant is associated with statin-induced side effectsJ Am Coll Cardiol200954171609161619833260
- LinkEParishSArmitageJSEARCH Collaborative GroupSLCO1B1 variants and statin-induced myopathy a genomewide studyThe N Engl J Med2008359878979918650507
- de KeyserCEPetersBJBeckerMLThe SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyPharmacogenet Genomics2014241435124263182
- FredricksonDSLeesRSA system for phenotyping hyperlipoproteinemiaCirculation19653132132714262568
- WilkeRARamseyLBJohnsonSGClinical Pharmacogenomics Implementation Consortium (CPIC)The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyClin Pharmacol Ther201292111211722617227
- SorticaVAFiegenbaumMLimaLOSLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern BraziliansClin Chem Lab Med201250344144822505549
- LeeHKHuMLuiSShHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patientsPharmacogenomics201314111283129423930675
- FuQLiYPGaoYLack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individualsEur J Clin Pharmacol20136961269127423263738
- YangGPYuanHTangBLack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patientsActa Pharmacol Sin201031338238620140004
- HuMTomlinsonBEffects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemiaAtherosclerosis2012223242743222749334
- CouvertPGiralPDejagerSAssociation between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapyPharmacogenomics2008991217122718781850
- Tachibana-IimoriRTabaraYKusuharaHEffect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitorsDrug Metab Pharmacokinet200419537538015548849
- PasanenMKNeuvonenPJNiemiMGlobal analysis of genetic variation in SLCO1B1Pharmacogenomics200891193318154446
- FedorovaSAReidlaMMetspaluEAutosomal and uniparental portraits of the native populations of Sakha (Yakutia): implications for the peopling of Northeast EurasiaBMC Evol Biol20131312723782551
- MatsumotoHCharacteristics of Mongoloid and neighboring populations based on the genetic markers of human immunoglobulinsHum Genet19888032072183056831
- FDA: Limit Use of 80 mg Simvastatin 1. FDA Consumer Health InformationUS Food and Drug Administration62011 Available from: http://www.fda.gov/downloads/forconsumers/consumerupdates/ucm257911.pdfAccessed June 8, 2011
- RamseyLBJohnsonSGCaudleKEThe clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 updateClin Pharmacol Ther201496442342824918167
- HouQLiSLiLLiYSunXTianHAssociation between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studiesMedicine (Baltimore)20159437e126826376374